Both in Pharmaceuticals
Cronos Group Inc. Common Share vs Damora Therapeutics
Over the past year CRON returned +6.7% and DMRA returned −24.9%; their daily moves had a correlation of 0.22.
CRON +6.7% DMRA −24.9%Growth of $1, one year, split-adjusted
| Metric | CRON | DMRA |
|---|---|---|
| Price | $3.35 | $21.09 |
| Market cap | $1.23B | $1.30B |
| Today | −2.76% | −2.86% |
| 1 month | +0.9% | +4.0% |
| 6 months | +25.0% | — |
| Year to date | +27.4% | — |
| 1 year | +39.0% | — |
| Revenue growth (YoY) | +59.5% | — |
| Gross margin | 65.8% | — |
| Net margin | 45.4% | — |
| P/E (TTM) | 17.6× | — |
| Price / sales | 4.8× | — |
| Net cash | $797.0M | $540.5M |
| Dividend yield | — | — |
| Volatility (60d) | 39.0% | — |
| Short % of float | 1.8% | 10.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).